Status:
COMPLETED
The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.
Lead Sponsor:
Hospital Civil de Guadalajara
Conditions:
Cardiorenal Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In double-blind clinical trial, determine renal recovery with two different furosemide strategies in patients with type 1 cardiorenal syndrome.
Detailed Description
In a patient with type 1 cardiorenal syndrome, we tried to compare two Furosemide strategies: both with a morning bolus, and randomized in two groups: Group A: Furosemide 80 mg every 24 hrs (morning)...
Eligibility Criteria
Inclusion
- Comply with both clinical diagnosis of acute kidney injury by serum creatinine according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines and acute decompensate heart failure as clinical assessed by the clinical team in charge.
- Have agreed and signed informed consent
Exclusion
- Patient in chronic dialysis either peritoneal dialysis or hemodialysis.
- History of being a renal transplant recipient
- History of acute kidney injury according to the KDIGO 2012 guidelines and / or renal replacement therapy in the last 3 months
- Pregnancy
- Impossibility to administer medication by the oral route
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04393493
Start Date
July 1 2017
End Date
April 1 2020
Last Update
September 14 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
HCG
Guadalajara, Jalisco, Mexico, 44240
2
Hospital Civil de Guadalajara
Guadalajara, Jalisco, Mexico, 44240